---

---

published : Today    crawled time : 07:00   

save search

---

HanxBio announces the publication of a research paper in Scientific Reports on preclinical evaluation of Narazaciclib for the treatment of acute myeloid leukemia (AML)
Published: 2024-04-23 (Crawled : 07:00) - prnewswire.com
ONTX | $0.9953 -5.61% 1.3M |

Health Technology

| Email alert Add to watchlist
publication treatment research preclinical for leukemia

---

Banking heavyweight Markus Sauerland, former CEO of Nomura Financial Products Europe GmbH, joins NowCM as COO and Co-CEO
Published: 2024-04-23 (Crawled : 07:00) - prnewswire.com
XYF | News | $3.9 2 |

Finance

| Email alert Add to watchlist
ARVL | News | $0.49 0.37% 2.5M |

Manufacturing

| Email alert Add to watchlist
europe ceo financial

---

HighByte Announces Series A Raise to Accelerate Growth in Industrial DataOps Market
Published: 2024-04-23 (Crawled : 07:00) - prnewswire.com
IT | $443.06 0.61% 0.0% 0 |

Commercial Services

| Email alert Add to watchlist
series growth market

---

Zscaler Research Finds 60% Increase in AI-Driven Phishing Attacks
Published: 2024-04-23 (Crawled : 07:00) - globenewswire.com
ZS | $172.05 0.63% 34K |

Technology Services

| Email alert Add to watchlist
research

---

Teledyne e2v and Airy3D collaboration delivers more affordable 3D vision solutions
Published: 2024-04-23 (Crawled : 07:00) - globenewswire.com
TDY | $404.08 0.68% 0.0% 0 |

Electronic Technology

| Email alert Add to watchlist
solutions vision collaboration

---

SFL - Acquisition of two LNG dual-fuel chemical carriers in combination with long term employment
Published: 2024-04-23 (Crawled : 07:00) - globenewswire.com
SFL | $12.81 0.79% 0.0% 200 |

Transportation

| Email alert Add to watchlist
acquisition

---

Together Selects nCino to Revolutionise its Lending Business
Published: 2024-04-23 (Crawled : 07:00) - globenewswire.com
NCNO | $29.64 0.78% 0.78% 2 |

Technology Services

| Email alert Add to watchlist
business

---

ImmunityBio Announces FDA Approval of ANKTIVA®, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Published: 2024-04-23 (Crawled : 07:00) - biospace.com/
IBRX | $5.0 1.21% 12M |

Manufacturing

| Email alert Add to watchlist
il-15 anktiva fda agonist approval bladder cancer for

---

Gainers vs Losers

75%

25%

Top 10 Gainers

MTTR | News M | $4.625 165.81% 5.5M |

AGBA | $2.615 109.2% 14M |

Finance

EDBL | News | $7.37 96.01% 650K |

PALI | $7.64 54.97% 14M |

Manufacturing

OPRT | News | $3.19 41.78% 3M |

Finance

PEGY | $0.0629 37.34% 110M |

Manufacturing

MLEC | $1.87 33.57% 1.6M |

n/a

ATGL | $3.66 27.97% 150K |

KULR | $0.5446 22.0% 6.8M |

Manufacturing

MDIA 4 | $2.205 21.15% 150K |

Consumer Services

---

Your saved searches

---